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Abstract: 
 
 
Parkinson patients have insufficient dopamine in specific regions of the brain, so attempts have 
been made to replenish the deficiency in the dopamine. Dopamine itself doesn't cross blood brain 
barrier, but its precursor, levodopa (LD) is actively transported into the CNS and is converted to 
dopamine in the brain. The bioavailability of LD is less than 10% with only 1% of administered 
oral levodopa penetrates the brain. Large doses of levodopa are required because much of the 
drug is decarboxylated to dopamine in the periphery, resulting in side effects that include nausea, 
vomiting, cardiac arrhythmias, and hypotension. To minimize the conversion to dopamine (DA) 
outside the central nervous system (CNS),  LD is usually co- administered with peripheral 
inhibitors of amino acid decarboxylase  (carbidopa and benserazide). In spite of that, other 
central nervous side effects such as dyskinesia, on-off phenomenon and end-of-dose 
deterioration still remain. 
 
Based on DFT calculations a novel dopamine prodrugs for the treatment of Parkinson’s disease 
that can improve the overall biopharmaceutical profile of the current medications to enhance 
effectiveness and to ease the use of the medications were synthesized, characterized, in vitro 
intra-conversion to their parent drugs and in silico pharmacokinetics and toxicity prediction were 
also studied. The synthesized dopamine prodrugs have a carboxylic group as a hydrophilic 
moiety and a hydrocarbon skeleton as a lipophilic moiety, where the combination of both groups 
ensures a moderate hydrophilic lipophilc balance value. The potential prodrugs are expected to 
give better bioavailability than the parental drug owing to improved absorption. Furthermore, 
these prodrugs are believed to be more effective than L-dopa because the latter undergoes 
decarboxylation in the periphery before reaching the blood– brain barrier. Additionally, the 
synthesized prodrugs can be used in different dosage forms (I.V., S.C., tablets, and others) 
because of their potential solubility in organic and aqueous media. For dopamine ProD 1 the 
experimental t½ values in 0.1N HCl, buffer pH 2.2, buffer pH 5.5 and buffer pH 7.4  were 60.3 
hours, 54.66 hours, 99.93 hours and 138.13 hours, respectively. Dopamine ProD 2 was readily 
converted in 0.1N HCl, buffer pH 2.2, pH 5.5 and pH 7.4 with half -life time (t½) of 48.34 hours, 
54.22 hours, 131.98 hours and 193.42 hours, respectively. Finally, in silico predicting of 
physiochemical parameters, ADMET (Absorption, Distribution, Metabolism, Excretion and 
Toxicity) properties, oral bioavailability and BBB permeability for the synthesized prodrugs 
were studied. The results revealed that no prodrug had a high risk of toxicity, and all the 
prodrugs showed good pharmacokinetic properties. Moreover, all synthesized dopamine 
prodrugs were found to obey Lipinski’s rule of five. 
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Chapter one 
 
 
1. Introduction 
1.1 Parkinson’s disease 
 
1.1.1 Symptoms of Parkinson’s disease 
 
Parkinson's disease (PD) was first described by English physician Dr. James Parkinson in 1817 
[1,2]. Parkinson's disease is classically defined as a progressive, idiopathic, neurodegenerative 
disease associated with four fundamental motoric signs: akinesia/bradykinesia, rest tremor, 
cogwheel rigidity and postural instability. A resting tremor is the first symptom in 70% of 
Parkinson's disease patients [3-5]. Moreover, parkinson’s disease can cause a wide range of non-
motor symptoms such as depression, loss of sense of smell, gastric problems, cognitive changes 
and many others [6]. 
1.1.2 Incidence and prevalence of Parkinson’s disease 
 
According to the Parkinson's Disease Foundation, Parkinson's disease affects about 1 million 
people in the United States [7-9] and more than 10 million people worldwide [7,10,11]. About 
60,000 people are diagnosed each year in the United States [7,9]. Although the disease itself is 
not fatal, the complications caused by Parkinson’s are the 14th leading cause of death in the 
United States [12]. The disorder occurs in all races, but Parkinson's is somewhat more prevalent 
among Caucasians [13]. Men were more likely than women to have Parkinson’s disease [14]. 
The average age of diagnosis is around 60, but approximately 5-10% of people with the 
condition develop "young-onset" Parkinson's disease before reaching age 50 [15]. 
 
1.1.3 Causes of Parkinson’s disease 
 
Although the exact cause of PD remains unknown, most cases are hypothesized to be a result of 
multiple factors acting together, including ageing, genetic susceptibility, and environmental 
exposures [16]. 
1.1.3.1 Environmental risk factors 
 
A number of environmental factors have been associated with an increased risk of Parkinson's 
including:pesticide exposure, living in rural areas (in industrialized countries), and drinking well 
water [17]. Conversely, certain environmental exposures seem to lessen the risk of Parkinson's 
disease, like cigarette smoking and the intake of caffeine [18]. 1-Methyl-4-phenyl-1,2,3,6- 
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tetrahydropyridine (MPTP) is the only toxic agent that has been directly linked to development 
of parkinsonism [19]. 
1.1.3.2 Genetics 
PD traditionally has been considered a non-genetic disorder; however, around 15% of 
individuals with PD have a first-degree relative to who has the disease [5]. Mutations in specific 
genes have been conclusively shown to cause PD. These genes code for alpha-
synuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or dardarin), PTEN-
induced putative kinase 1 (PINK1), DJ-1 and ATP13A2 [20,21].In most cases, people with these 
mutations will develop PD.  
1.1.4 Pathology of Parkinson’s disease 
The pathologic hallmark of the Parkinson’s disease result from reduced activity of dopamine-
secreting cells caused by cell death in the pars compacta region of the substantia nigra [22]. The 
other major neuropathological symptom of PD is the existence of Lewy bodies which is formed 
mainly by an abnormal accumulation of the protein α-synuclein bound to ubiquitin in the 
damaged cells [23]. The leading cause of neuronal death is not known. Proteosomal along with 
mitochondrial dysfunction are possible causes [24]. 
1.1.5 Treatment of Parkinson’s disease 
1.1.5.1 Anticholinergic drugs 
These medications were the first available pharmacological agents used in the treatment of 
Parkinson's disease. They block the effect of acetylcholine, another brain chemical, to re-balance 
its levels with dopamine. They include benztropine, biperidine and benzhexol. Nowadays, all 
these drugs are rarely used because of the relatively modest benefits that they provide compared 
with their side effect profile [25]. 
1.1.5.2 Dopamine replacement therapy 
Levodopa (LD, L-dopa), coupled with carbidopa, a peripheral decarboxylase inhibitor (PDI), 
remains the gold standard of symptomatic treatment for Parkinson disease. Carbidopa inhibits 
the decarboxylation of levodopa to dopamine in the systemic circulation, allowing for greater 
levodopa distribution into the central nervous system [26]. Levodopa provides the greatest 
antiparkinsonian benefit for motor signs and symptoms, with the fewest adverse effects in the 
short term; however, long-term treatment leads to involuntary movements and response 
fluctuations which add to the complexities of later disease-management. In addition, preclinical 
evidence suggests that levodopa is toxic to dopaminergic neurons. Once fluctuations and 
dyskinesias become problematic, they are difficult to resolve [26,27]. 
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1.1.5.3 Dopamine agonists 
Dopamine agonists have a complex pharmacology acting directly on post- and presynaptic 
dopamine receptors to mimic the effects of endogenous dopamine (DA). They include ergot 
derivatives such as bromocriptine, lisuride, pergolide, and cabergoline and other agents which do 
not possess the ergot structure such as pramipexole and ropinirole [28].  
Initially, dopamine agonists were believed to be effective only as adjunct therapy to L-dopa [29]. 
A few years later, they are accepted as primary treatment in early PD with a  delay in the 
development of dyskinesia [30].The use of DA agonist in the early PD provide moderate 
symptomatic benefit and delay the introduction of L-dopa [31]. However, DA agonists are not as 
effective as L-dopa in the later stages of PD, and they still produce many of the dopaminergic 
side effects associated with L-dopa use, such as nausea, vomiting, hypotension, hallucinations, 
and psychosis. [32]. 
1.1.5.4 MAO-B Inhibitors 
 
Monoamine oxidase (MAO) type B is an enzyme that naturally breaks down several chemicals in 
our brain, including dopamine. By blocking this enzyme, the breakdown of the chemical 
messenger dopamine within the brain will be prevented and therefore prolong the action of 
levodopa [33]. There is considerable laboratory evidence that MAO-B inhibitors do exert  
antioxidant and antiapoptotic activity in experimental models, which may potentially translate 
into long-term clinical neuroprotective effect [34]. 
Two MAO-B inhibitors, selegiline and rasagiline, are currently approved for the symptomatic 
improvement of early Parkinson's disease and to reduce off-time in patients with more advanced 
Parkinson's disease and motor fluctuations related to levodopa [35]. 
1.1.5.5 COMT inhibiters 
When peripheral decarboxylation is inhibited by carbidopa or benserazide, the main metabolic 
pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone 
and tolcapone are new potent, selective COMT inhibitors. They have the ability to block the 
COMT enzyme from converting levodopa into a useless form (3-O-methyldopa),  thus making 
more levodopa in the brain available and helping to reduce PD symptoms. Dopaminergic and 
gastrointestinal effects are the main adverse effects of the COMT inhibitors [36]. 
1.1.5.6 Amantadine 
Amantadine hydrochloride was originally used as an antiviral for the treatment of influenza, but 
was coincidentally has been shown to improve the symptoms of Parkinson's disease [37]. 
Amantadine is a weak antagonist of the NMDA-type glutamate receptor, increases dopamine 
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release, and blocks dopamine reuptake [38]. It was reported that amantadine given as adjuvant to 
levodopa can markedly improve motor response complications [39]. 
 
1.2  Dopamine 
 
Dopamine is a natural neurotransmitter that needs to turn on the five dopamine receptors in the 
brain, D1, D2, D3, D4 and D5 to function through the CNS. Dopamine is produced in several areas 
of the brain, including the substantial nigra and the ventral tegmental area. Also is considered a 
neurohormone as dopamine is secreted from the gland of hypothalamus and its main function as 
a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary [40]. 
Dopamine production in human body is one step during the catecholamine biosynthesis that 
starts from phenylalanine to tyrosine, levodopa and then dopamine (Figure 1). This cascade is 
accomplished and catalyzed with the aid of three enzymes. The rate limiting enzyme is tyrosine 
hydroxylase, which can then be inhibited by the catecholamine neurotransmitters to keep the 
proper regulation of dopamine levels all over the body [41]. Dopamine plays several and variant 
roles among the body, including CNS, circulatory, renal, digestive and immune systems. Its role 
in the CNS is the cornerstone in controlling the body’s movement, motivation, emotion and the 
feel of pleasure. Dopamine can be supplied as a medication that acts on the sympathetic nervous 
system, producing effects such as increased heart rate and blood pressure [40]. 
 
O-
O
NH3
+
O-
O
NH3
+
O-
O
NH3
+
HO
HO
HO
HO
HO
NH2
L-Phenylalanine L-tyrosine
L-DOPA
Dopamine
Phenylalanine hydroxylase
Tyrosine 
hydroxylase
Aromatic L- amino acid Decarboxylase
 
Figure 1 : Production of dopamine inside human body 
 
Dopamine deficiency as a result of the loss of dopamine secreting neurons in the substantial 
nigra in the brain combined with the formation of Lewybodies (intracytoplasmic proteinaceous 
inclusions of fibrillar-synuclein) causes impaired movement and tremor, a neurodegenerative 
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disorder called Parkinson disease (PD) [42]. However, giving the PD patient external dopamine 
as a treatment is not a choice, as dopamine is a water-soluble drug that does not satisfy the 
characteristics of a substance that can enter the brain. This substance must penetrate the highly 
selective and lipophilic membrane that protects the brain, the blood brain barrier (BBB) [40].  
1.3  Prodrug approach 
1.3.1 The principle of prodrug approach 
Many therapeutic drugs have adverse properties that may become pharmacological, 
pharmaceutical or pharmacokinetics barriers in the clinical drug application [43]. Development 
of new chemical entities with desirable efficacy and safety can be achieved to overcome the 
undesirable physicochemical, biological and organoleptic properties of some existing drugs. 
However, this is a challenging, expensive and time consuming process that requires very 
expensive phase I, II and III clinical trials [44]. So that,  it becomes much more feasible to 
modify and improve the properties of already existing drugs through exploring the prodrug 
approach which may represent a life-cycle management opportunity [43]. 
 
Historically, the term prodrug was first introduced in 1958 by Albert [45]. Prodrugs are 
pharmacologically inactive chemical derivatives of a drug molecule that  converted to its active 
form by enzymatic and/or chemical transformation within the body [46]. In both drug discovery 
and development, prodrugs have become an established tool for improving physicochemical, 
biopharmaceutical or pharmacokinetic properties of pharmacologically active agents [47]. 
Approximately, 10% of all worldwide marketed medications can be categorized as prodrugs,  
20% of medicines that were approved between 2000 and 2008 were prodrugs and when focusing 
on 2008 alone, 33% of all approved small-molecular-weight drugs were found to be prodrugs. 
Therefore, nowadays the interest in prodrug approach become increasingly popular and 
successful in pharmaceutical industries [48,49]. 
 
Prodrugs can be classified according to two major criteria, chemical classes (carrier-linked 
prodrugs, bioprecursors, sit-specific chemical delivery systems, etc.) and mechanism of 
activation (enzymatic versus nonenzymatic, activation by oxidation, reduction or hydrolysis, 
catabolic versus anabolic reaction) [50]. 
 
1.3.2 Prodrug activation 
Successfully designed prodrug should be converted to its parent drug. Generally, activation 
process involves metabolism by enzymes distributed throughout the body. The most important 
enzymes in the bioconversion of prodrugs are hydrolytic enzymes such as esterases and 
amidases. However, non-hydrolytic enzymes, including all cytochrome P450 enzymes, are able 
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to catalyze the bioconversion of ester and amide-based prodrugs [51]. Enzymes accelerate the 
rate of chemical reactions that the substrate (drug) might undergo in physiological environment. 
The rate constants for a large majority of enzymatic reactions is 10
10
 to 10
18
 fold the non-
enzymatic reactions [52]. 
Prodrugs that are designed to be activated by natural enzymes such as esterases and amidases 
may be tackled by a premature hydrolysis during the absorption phase in enterocytes of 
gastrointestinal tract, this might produce more polar and less permeable prodrug which results in 
a decreased bioavailability [52], while if the prodrug is activated by cytochrome P450 enzymes 
which are responsible for 75% of the enzymatic metabolism of prodrugs, a genetic 
polymorphisms might persist and then lead to variability in prodrug activation and thus affect the 
efficacy and safety of designed prodrugs [53].  Thus, it might be difficult to predict the 
bioconversion rate of the enzymatic hydrolysis of the prodrug and hence a difficulty in predicting 
their pharmacological or toxicological effects. Moreover, the rate of hydrolysis is not always 
predictable, and bioconversion can be affected by various factors such as age, health conditions 
and gender [54-56]. 
Modern computational methods based on molecular orbital and molecular mechanics methods 
are explored for the design of innovative prodrugs for drugs containing hydroxyl, phenol, or 
amine groups. For example, mechanisms of some enzyme models that have been utilized to 
understand enzyme catalysis have been recently investigated by Karaman’s group and used for 
the design of some novel prodrug linkers [57-60]. The traditional prodrug approach was focused 
on altering various physiochemical parameters, whereas the modern computational approach, 
considers designing prodrugs through  attaching appropriate linkers with drugs having poor 
bioavailability which upon exposure to physiological environments release the parent active 
drugs in a programmable (controlled) manner resulting in an improvement of their 
bioavailability. With the possibility of designing prodrugs with different linkers, the release rate 
of the parent active drugs can be controlled [61]. 
 
1.3.3 Applications of prodrug approach 
1.3.3.1 Improving solubility and dissolution rate of drugs 
 
Poor solubility of a drug will be a major issue when dissolution of the drug from a dosage form 
is the rate limiting step [62]. It has been reported that about 35-40 % of drug discovery 
compounds have poor aqueous solubility [63]. There are numerous formulation approaches, such 
as salt formation and solubilizing excipients, have been used to overcome this barrier. Prodrugs 
offer an alternative tool to increase the aqueous solubility of the parent drug molecule by 
attaching ionizable or polar neutral groups, such as phosphates, amino acids, or sugar moieties 
[64-66]. Enzymes such as phosphatases, esterases, glucosidase, amidases or peptidases in plasma 
or other tissues can then breakdown the molecules into its active form. Fosphenytoin is a good 
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example of a prodrug which by the addition of a phosphate group has improved the aqueous 
solubility of phenytoin by a factor of 7,000 fold [67]. 
1.3.3.2 Enhancing permeability and absorption 
For drug to be transported to its site of action it should pass through several lipid membranes; 
therefore, membrane permeability has a considerable influence on drug efficacy [68]. Prodrug 
strategies are most commonly employed to promote membrane permeation and either oral or 
topical absorption by increasing drug lipophilicity via masking polar and ionizable groups within 
a drug molecule [69]. A hydrophilic hydroxyl, thiol, carboxyl, phosphate, or an amine group on 
the parent drug can be converted to more lipophilic alkyl or aryl esters, and these prodrugs are 
readily converted to the parent drugs via hydrolysis catalyzed by esterase enzyme [70,71]. An 
example of this type of prodrug is oseltamivir which is an ethyl ester prodrug and undergoes 
rapid conversion by carboxylesterase to its parent drug. The bioavailability of the more lipophilic 
oseltamivir is almost 80%, whereas the corresponding value for free carboxylate is as low as 5%. 
[67]. 
Another method to increase the oral absorption is to design prodrugs, which have structural 
features similar to substrates that are absorbed by carrier-mediated transport [67]. Enalapril is an 
example of an ester prodrug which improves the bioavailability from 3% (active drug) to 40%. 
The ethyl ester moiety increases lipophilicity and is also a substrate of the PEPT1transporter 
[72]. 
1.3.3.3 Changing the Distribution Profile 
Selective delivery of drugs to particular tissues can increase their therapeutic activity and 
decrease their side effects. For decades, attempts have been made to achieve site-selective drug 
delivery by utilizing different macromolecular strategies and nanotechnologies. Unfortunately, 
these methods lack clinical success. Therefore, scientists have focused their interests on other 
approaches. Today, the prodrug approach is one of the most promising site-selective drug 
delivery strategies which exploit target cell- or tissue- specific endogenous enzymes and 
transporters [25]. One example is the prodrug capecitabine which is metabolized initially in the 
liver and subsequently in tumor cells to form the anticancer agent 5-fluorouracil [72]. 
1.3.3.4 Protecting from Rapid Metabolism 
The first pass metabolism in the gastrointestinal tract and liver may greatly reduce the oral drug 
bioavailability [73]. Sublingual or buccal administration and modified or controlled release 
formulations has been formed to bypass this problem [74]. The prodrug approach can also 
protect the rapid metabolic breakdown of the drug and thereby increase its oral bioavailability by 
masking the metabolically labile functions [75]. 
1.3.3.5 Taste masking 
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Bitterness of the drug is the major reason for patient incompliance. In order to eliminate the 
bitter taste of a drug and hence increasing its efficacy, the prodrug approach can be used either 
by decreasing the drug solubility in saliva or by masking the functional group that is responsible 
for the drug’s binding to the taste receptors located on the tongue [76]. 
1.3.4 Prodrug approaches for the CNS delivery 
 
One of the major difficulties in terms of drug delivery to the central nervous system (CNS) is the 
inability of many therapeutical compounds to pass through the blood-brain barrier (BBB) [77]. 
BBB is a highly selective permeable barrier that is formed by brain endothelial cells, which are 
connected by tight junctions. BBB has no fenestrations, exhibit very low pinocytic activity and 
are surrounded by astrocyte foot processes that are part of its structure and mediate its 
permeability [78].The BBB is necessary to protect the central nervous system from potentially 
harmful chemicals while selectively facilitating the transport of essential molecules into the CNS 
and maintaining an optimal stable environment for brain function [79]. 
 
Due to its unique properties, passage across the BBB often becomes the main limiting factor for 
the delivery of potential CNS drugs into the brain parenchyma. In fact, it is estimated that more 
than 98% of small-molecular weight drugs and practically 100% of large-molecular weight drugs 
developed for the CNS diseases do not readily cross the BBB [80]. 
 
The penetration into the BBB  can be achieved by one of the three main ways. First, a drug will 
diffuse freely through the membrane if it obeys Lipinski’s rule of five, suggested and applied 
since 1997 [81]. Lipinski suggests that for any substance to penetrate the lipophilic membranes 
all over the body passively, it must have these properties, a molecular mass less than 500, a 
lipophilicity expressed as log p not greater than 5, no more than 5 hydrogen bond donors and a 
number of hydrogen accepting groups less than 10. Furthermore, lipid soluble (lipophilic) 
molecules with a molecular mass under 400–600 Da can go through  the BBB by means of a 
passive diffusion mechanism [81,82]. Secondly, essential nutrients including glucose, amino 
acids and nucleosides can be transported actively by carriers (carrier-mediated transport). Yet, 
proteins and peptides are thirdly facilitated to be transport either by specific receptors (receptor 
mediated endocytosis) or by electrostatic interactions with endothelial membrane (adsorptive-
mediated transcytosis) [83-86]. 
 
Enhancement of drug permeability to BBB can be achieved by different approaches: 1) 
administration of the drug into CNS directly, 2) disruption of the BBB temporarily, thus 
enhancing its permeability, 3) prodrug strategy by chemical alteration of drug and 4) 
Formulation strategies using colloidal carriers such as  polymeric solid lipid nanoparticles 
(SLNs), dendrimers, polymeric micelles, and liposomes [87].  
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The prodrug strategy is widely used to optimize physicochemical properties that allow for 
passive diffusion via the transcellular route or to insert structural features necessary to serve as a 
substrate for one of the endogenous influx transport systems[88]. 
 
1.3.4.1 Lipophilic prodrugs 
 
Lipophilic prodrugs can be achieved using the lipidization approach or that of chemical delivery 
systems (CDS). A very simple approach to increase the CNS entry of hydrophilic molecules 
would be via reversibly masking the polar functionalities within such compounds. This is 
referred to as a lipidization of molecules. Although the lipidization with lipophilic drug 
analogues often results in diminished therapeutic effect by enhanced toxicity or decreased 
activity of the drug, the lipidization through prodrugs offers a probability to enhance CNS 
delivery of  polar drugs. However, this approach does not usually produced effective therapeutic 
outcomes [77,89]. The CDS approach requires multiple steps bioactivation for conversion to 
active drugs. It captures the drug inside the brain by converted the prodrug  into a more 
hydrophilic derivatives after crossing CNS. Thus reduce the efflux of drug from the CNS and 
provide a sustained release for it [90,91].    
1.3.4.2 Carrier-mediated prodrugs 
 
This approach based on attaching the parent drug to an endogenous transporter substrate for 
example amino acids, glucose, and other hexoses,  which can recognize the prodrug as its own 
substrate and enable it to enter the CNS. Then, bioconversion to parent drug occur [92]. Most 
widely used transport systems in prodrugs approach are glucose transporter (GLUT1),large 
neutral amino acid transporter(LAT1), monocarboxylic acid transporter (MCT) and peptide 
transport systems [93,94]. 
1.4  Problem statement 
Patients with Parkinson’s disease  have insufficient dopamine in specific regions of the brain, so 
attempts have been made to replenish the deficiency in the dopamine [95]. Unfortunately, 
peripherally administered (outside of the central nervous system) dopamine is not effective 
because it cannot cross the blood brain barrier. The reason for its inability to cross the BBB has 
to do with at least two influencing factors.  The first is that dopamine is a hydrophilic molecule 
which is expected to exist primary in the ionized forms (Figure  2) in a  physiologic environment 
of pH 7.4 (blood circulation) resulting in a greater degree of difficulty in crossing cell 
membranes.  The second is the absence of a transporter for dopamine to pass the blood brain 
barrier into the brain [96]. 
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Figure 2 : Ionized form of dopamine at physiological environment 
 
However, the precursor to dopamine, LD (Figure 3), was and still the best choice of treatment for 
this disease. LD is able to get into the brain via a large neutral amino acid carrier or L (leucine) 
system [97]. Once LD gets inside the brain it can then be metabolized by dopa decarboxylase or 
amino acid decarboxylase to form dopamine within the dopaminergic neurons within the 
substantia nigra [98].  
 
 
HO
HO
OH
O
NH2
 
 
Figure 3: Chemical structure of Levodopa 
 
Because much of the drug is decarboxylated to dopamine in the periphery, high doses of LD are 
required, resulting in side effects that include nausea, vomiting, cardiac arrhythmias, and 
hypotension [99]. These drawbacks of LD are the known reason of disability in PD patients [100, 
101]. They can be explained according to this manner: In the normal brain the basal ganglia 
always maintained to satisfy the brain needs of dopamine for motor control and others, but LD 
oral administration have a low bioavailability of 10% with only 1% of LD reaching the brain. 
This is due to the erratic gastrointestinal metabolism the drug faces before it attaches to the  l-
amino acid carrier that transports it actively through the duodenum where it enters the blood 
stream intact [102-107]. With the co-administration of either carbidopa or benserazide, an 
increase of LD bioavailability by two-fold was observed with only 5% to 10% of administered 
LD enters the brain [108,109].  As a result, lessened amounts of dopamine put the brain under 
fluctuations that are hard to accommodate [110,111]. To minimize the conversion to DA outside 
the CNS,  LD is usually given in combination with peripheral inhibitors of amino acid 
decarboxylase such as carbidopa and benserazide. In spite of that, other central nervous side 
effects such as dyskinesia, on-off phenomenon and end-of-dose deterioration still remain [112]. 
 
HO
HO NH2
H
OH
HO
HO NH3
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The main factors responsible for the poor bioavailability and the wide range of inter- and intra-
patient variations of plasma levels are the LD physicochemical properties such as  low water and 
lipid solubility which resulted to unfavorable partition, and the high susceptibility to chemical 
and enzymatic degradation [113]. Starting from these considerations the prodrug approach has 
been applied to dopamine in order to overcome its metabolism problems and to improve its 
bioavailability. 
1.5  Thesis Objectives 
1.5.1 General objectives 
The main objective of this study is to synthesize new prodrugs for the treatment of Parkinson's 
disease that have the potential for higher bioavailability than the current medications when given 
in different dosage forms. 
For achieving this goal, the dopamine prodrugs physiochemical properties must have the 
following: (i) to be soluble in physiochemical environment; (ii) to have a moderate hydrophilic 
lipophilic balance (HLB) value; (iii) to provide upon chemical cleavage a safe and non-toxic by-
products. 
By achieving these requirements, the following objectives may be fulfilled: (i) a high disposition 
of the prodrug into the body tissues; (ii) the capability to use the anti-Parkinson's drug in 
different dosage forms; (iii) a chemically driven sustained release system that release the 
dopamine in a controlled manner; and (iv) a drug with a high bioavailability and efficient 
pharmacokinetic properties.   
1.5.2 Specific objectives of our work are 
1. To synthesize dopamine prodrugs for the treatment of PD that has the potential for higher 
bioavailability than the current medications by using different linkers. 
2. To characterize the proposed prodrugsusing several analytical techniques. 
3. To perform in vitro kinetic studies for the synthesized dopamine prodrugs at different 
pHs mimicking the physiological media. 
4. To predict oral bioavailability, pharmacokinetics, BBB permeability and toxicity of 
dopamine prodrugs using in silico computational software. 
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1.6  Research Questions 
1. Would it be possible to link dopamine to the linkers via a chemical synthesis? 
2. Would the synthesized prodrugs be capable of in vivo releasing the parent drug 
(dopamine) in a sustained release?  
3. Does the synthesized prodrug have physiochemical properties which could lead to a good 
pharmacokinetic properties and a high bioavailability?  
4. Does the synthesized prodrug have the capability to  be used in different dosage forms ? 
5. Does the synthesized prodrug have the ability to cross BBB ? 
6. Does the synthesized prodrug have the drug-like properties ? 
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Chapter two 
Literature Review 
Several attempts have been made to overcome the patient’s symptoms of  PD, therefore 
enhancing his lifestyle and the ability to live normally. In this section, I am going to discuss the 
different dopamine prodrug approaches which were done by medicinal chemists to enhance its 
bioavailability. 
2.1 Lipophilic Dopamine prodrugs 
2.1.1 Ester dopamine prodrugs 
 
Dopamine have poor permeation across the BBB and other cell membranes due to its complete 
ionization at  physiological pH. So it cannot be used for PD [114]. To overcome these problems, 
Casagrande et al. and Borgman et al. have prepared a number of lipophilic 3,4-O-diesters 
prodrugs of DA (54-58) (Figure 4) as a latent lipophilic derivatives of DA to be used in the 
therapy of parkinsonism, hypertension and renal failure [114,115]. But the results showed that O-
acetylation was not enough to provide entry into CNS  while preservation intrinsic dopaminergic 
activity and N-alkylation of the DA molecule are also required. 
 
RCOO
RCOO
CH2CH2NH2
1. R = CH3
2. R = CH(CH3)2
3. R = C(CH3)3
4. R = C6H5
5. R = C2H5O  
 
Figure 4 : A series of lipophilic 3,4-O diesters dopamine  pro-drugs. 
 
 
2.1.2 Chemical delivery systems 
 
Chemical delivery systems (CDSs) have been established to enhance the permeation of DA to 
central nervous system. These prodrug devices have been prepared by joining DA with a 
pyridinium/dihydropyridine redox carrier. A dihydropyridinium-type CDS is  lipophilic  enough 
to cross the membrane of CNS  by passive transport and then undergoes an enzymatic oxidation 
to an ionic pyridinium precursor, this lead to locked compounds in the CNS [116]. (CDS) used 
also for brain-enhanced delivery of neurotransmitters, steroids, anticonvulsants, antibiotics, 
antiviral, anticancer, neuropeptides and their analogs [116-118].This carrier enables the prodrug 
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to cross BBB and then be oxidized to a quaternary precursor that is retained in the CNS, to 
provide a DA in a sustained release form (Figure 5). 
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Figure 5 : Dopamine delivery from pyridinium/dihydropyridine redox carrier system. 
 
The use of the dihydropyridine is actually restricted due to instability of its 5,6-double bond, 
which undergoes air-oxidation and/or hydration. This oxidation/hydration reaction  yields  6-
hydroxy-1,4,5,6-tetrahydropyridine, which does not undergo enzymatic oxidation in vivo to give 
the corresponding quaternary pyridinium salt [7]. In order to overcome this problem, Carelli et 
al. suggest an interconvertible tetrahydrobipyridine/pyridinium salt (Figure 6) by irreversible 
dimerization of two pyridinyl radicals accomplish by one-electron electro-chemical reduction of 
pyridinium salts as nicotin-amide coenzymes or their models. In contrast with monomeric 
dihydropyridines, the tetrahydrobipyridines  are more stable and easily oxidized back to the 
compound pyridinium salts by chemical oxidants or by oxygenase and peroxidase enzymes 
[118]. 
 
(H3C)3COCO
(H3C)3COCO
H
N
O
N
N
N
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OCOC(CH3)3
OCOC(CH3)3
CH3
CH3
 
 
Figure 6 : Chemical structure of tetrahydrobipyridine. 
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2.2 Carrier-mediated prodrugs 
2.2.1 Peptide transport-mediated prodrugs 
2-Amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (DOPH), an amide 
prodrug of DA, has been earlier proposed by Giannola et al. (Figure 7) [119]. It is synthesized by 
condensation of dopamine with a neutral amino acid to be able to interact with the BBB 
endogenous transporters and easily enter the brain. (DOPH) has the capacity to be slowly 
cleaved by cerebral enzyme (t½ 460 min) and produce free dopamine in the brain, but it 
undergoes a rapid hydrolysis in human plasma (t½ 28 min). Chemical stability studies on DOPH 
showed that no DA release occurred in the gastrointestinal tract and the prodrug was able to pass 
through a simulated intestinal mucosal membrane. 
 
 
HO
HO
HN
O
NH2
 
 
Figure 7  : Chemical structure of 2-amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (DA-
PHEN) 
 
In another study and in attempt to enhance BBB permeability of dopamine, More and Vince 
focused on the glutathione uptake transporters that are located on the luminal side of the BBB. 
The broad substrate specificity displayed by these transporters provides vast opportunity for 
rational prodrug design. The design of glutathione transporter targeted prodrug (Figure 8) 
involved three components: the carrier, glutathione (GSH), the active drug, and a suitable linker 
for conjugation of the carrier with the drug molecule. The prodrug in (Figure 9) in which the 
dopamine is covalently linked via amide bond to glutathione (GSH) showed high affinity for the 
GSH transporter at the BBB, released dopamine at the active site and possessed a good stability 
balance between the periphery and brain [120]. 
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Figure 8: A rational for a prodrug design  
 
 
 
 
 
Figure 9: Chemical structure of the anti-Parkinson’s prodrug of dopamine. Shown in green is the carrier, 
metabolically stable glutathione analogue; in blue is the linker, mercaptopyruvic acid, and in red is the active 
drug moiety. 
 
N-3,4-bis(pivaloyloxy)-dopamine-3-(dimethylamino)propanamide (PDDP) (Figure 10), a brain 
specific derivative of dopamine, was designed and prepared, which consists of a brain targeted 
ligand, N,N-dimethyl amino group, and two dipivaloyloxy groups for lipophilic modification. 
Tissue distribution, brain bioavailability, and therapeutic efficacy of PDDP were evaluated and 
compared with L-DOPA and another brain dopamine prodrugs without N,N-dimethyl amino 
group which showed a more marked accumulation in rats brain microvascular endothelial cells 
than brain dopamine prodrugs through an active transport process. Following IV administration, 
the concentration of PDDP in the CNS was 269.28- and 6.41-folds higher than that of L-DOPA 
and brain dopamine prodrugs at 5 min, respectively. Therefore, PDDP would be a promising 
drug candidate that can be applied for targeted PD treatment [121]. 
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Figure 10 : Chemical structure of N-3,4-bis(pivaloyloxy)-dopamine-3-(dimethylamino)propanamide (PDDP) 
 
2.2.2  GLUT1 carrier-mediated prodrugs 
With the aim of overcoming the problem of the low BBB permeability of dopamine, a novel 
glycosyl derivatives of dopamine were synthesized which have the ability to be transported by 
GLUT1. Fernandez and coworkers  described the synthesis and biological activities of several 
glycosyl derivatives of dopamine by conjugating sugar with dopamine through a succinyl linker, 
carbamate bond, glycosidic and ester bonds. They linked  the amino group of dopamine to the C-
6 , C-3 and C-1 of the sugar through a succinyl linker (compounds 6-8 in Figure 11) or a 
carbamate bond (compounds 9-13 in Figure 11).  In another series,  the sugar was linked to the 
phenolic groups of dopamine through a glycosidic bond (compounds 14 and 15 in Figure 11) and 
ester bonds(compounds 16-18 in Figure 11). The affinity of the these prodrugs for glucose 
carrier GLUT-1 using human erythrocytes was also tested [122,123]. When incubated with the 
brain extracts, the nature of the bond that links DA with glucose affected the rate in which the 
prodrug releases dopamine. The glycosyl conjugates substituted at the C-6 position of  the sugar 
were more potent inhibitors of glucose transport in contrast to that of C-1 and C-3  substituted 
derivatives. From the studied compounds, the carbamate derivatives 9, 11 and 12 were the 
prodrugs of choice, in particular compound 9, which showed the best affinity for GLUT-1, even 
with higher affinity than glucose itself [124,125]. 
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Figure 11: Glycosyl dopamine derivatives. 
 
In another study, Bonina et al. and Ruocco et al. have prepared dopamine glycoside prodrugs by 
attaching DA to C-3 position of glucose (19 in Figure 12) and to C-6 of galactose (20 in Figure 
12) by a succinyl spacer. Pharmacological studies showed that these two prodrugs were found to 
be more active than LD in reversing reserpine-induced hypo-locomotion in rats.  
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Figure 12 : Chemical structures of glycosuccinyl-derivatives of dopamine. 
 
2.3 Enzyme Model 
 
Despite that some success has been obtained using the different strategies by which prodrugs of 
dopamine were used to supply dopamine in adequate concentrations and sustained release 
manner, the prodrugs chemical approach involving enzyme catalysis has many limitations related 
to many intrinsic and extrinsic factors that can affect the process. For example, the activity of 
many prodrug-activating enzymes may be varied due to genetic polymorphisms, age-related 
physiological changes, or drug interactions, causing variation in clinical effects [126-130]. 
 
Karaman’s group has explored a number of intra-molecular processes to gain insight into 
enzyme catalysis, toward the development of prodrug linkers that can be covalently attached to 
commonly used drugs which could have the potential for higher bioavailability over existing 
medications and would be chemically, and not enzymatically, be converted to release the active 
drugs in a controlled manner [131-166], by using ab-initio and density functional theory (DFT) 
molecular orbital methods.  
 
Recently they have been designed a number of dopamine prodrugs to be used in the treatment of 
Parkinson‘s disease with a higher bioavailability than the current medication. These designed 
prodrugs have the following physicochemical features :(i) owning moderate hydrophilic 
lipophilic balance  (ii) soluble in physiological environment  (iii) deliberate dopamine  in a 
controlled manner, and  (iv) undergo chemical cleavage to nontoxic by-products [96]. 
 
They explored the proton transfer reaction in some of Kemp‘s acid amide derivatives 21-31 
(Figure 13) by using enzyme models as potential linkers to be linked to amine-drugs [153]. 
Based on the DFT calculations on proton transfer mechanism of these acid amides,  two 
dopamine derivatives were proposed. As shown in (Figure 14), ProD 32 and ProD 33 have a 
carboxylic group as a hydrophilic moiety and the rest of the prodrug as a lipophilic moiety, 
where the combination of  both moieties secures a moderate HLB. Furthermore, at physiological 
pH in the blood circulation the expected predominant form of dopamine is the ionized form 
while its prodrug 32 and prodrug 33 are predicted to exist in the ionic and free acid forms. So, 
ProD 32 and ProD 33 may have a higher bioavailability than dopamine due to improved 
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absorption. Also, the designed prodrugs can be used in many dosage form (e.g. enteric coated 
tablets) because they are  predicted to be soluble in organic and aqueous media due to the ability 
of the carboxylic group to be converted to the corresponding carboxylate anion in physiological 
environments of pH 5.0-7.4 (intestine and blood circulation). 
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Figure 13 : Chemical structures of Kemp’s acid amides 21-31. 
 
 
H3C CH3
O
OH O
NH
OH
OH
H3C CH3
O
OH O
NH
OH
OH
H2N
OH
OH
H2N
OH
OH
H3C CH3
O
OHO
OH
H3C CH3
O OH
O
OH
H2O
PH 5.5-7.5
H2O
PH 5.5-7.5
32
33  
 
Figure 14 : Dopamine prodrugs, ProD 32- ProD 33. 
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Chapter Three 
Experimental Part 
 
This chapter consists of three major parts. The first one is the synthetic part which concerns with 
the reactions, reagents, solvents and materials used, the second is the Kinetic studies part which 
describes the specific preparations and analysis used to investigate dopamine prodrugs 
hydrolysis in different pH solutions using the HPLC instrument and the third part is in silico 
predicting of physiochemical parameters, ADMET (absorption, distribution, metabolism, 
excretion and toxicity) properties, oral bioavailability and BBB permeability for the synthesized 
prodrugs. 
3.1 Part one 
3.1.1 Chemicals and Instrumentation. 
3.1.1.1 Reagents 
1,2-cyclohexanedicarboxylic anhydride, hexahydro-4-methylphthalic anhydride, sodium hydride 
(NaH), thin layer chromatography (TLC), glacial acetic acid (>99.8%) and pure standard of 
dopamine are all purchased from Sigma Aldrich.  
3.1.1.2 Solvents 
High purity chloroform (CHCl3), tetrahydrofurane (THF) and diethyl ether (> 99%), were used 
directly from the bottles and all were purchased from Sigma Aldrich. Distilled water was 
obtained from a distillatory device available at Karaman’s lab. HPLC grade solvents of 
methanol, and water were purchased from J.T. Paker.  
3.1.1.3 Instrumentation and substance identification 
Chemical hazards fuming hood, vacuum pumps, hotplates, available at Karaman’s Lab in the 
Faculty of Pharmacy, Al-Quds University. FTIR, pH meter and rotary evaporator are available at 
Al-Quds University. HPLC was done at Al-Quds University and at Jerusalem Pharmaceutical 
Company in Ramallah. 
1
H-NMR and LC/MS were taken at the Hebrew University and at Jordan 
Center For Pharmaceutical Research (JPRC) respectively. 
3.1.1.3.1 Melting point determination by capillary method. 
Capillary method is commonly used in chemistry labs to determine the melting points of solid 
substances. This technique is easy and requires a small amount of the material. It is performed by 
introducing a small amount of the solid into a one end sealed capillary tube, which is then fixed 
into a thermometer, then dipped into an oil bath. Heating of the oil bath should be done slowly 
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and gently, to ensure uniform heating of the sample and the thermometer. Then, the temperature 
range over which the sample starts to melt is recorded to be as the melting point of the material. 
3.1.1.3.2   High  performance Liquid Chromatography HPLC.  
 
HPLC from Waters 2695 (Israel, Shimadzu corp. Japan), and waters Micromass® Masslynx ™ detector 
with Photo diode array (PDA) (Waters 2996: Israel). Data acquisition and control were carried out using 
Empower ™ software (Waters: Israel). 
Analysis was done using C18, 4.6 mm x125 mm, 5 μm particle size, protected by XBridge® C18 guard 
column. Micro filters 0.45μm porosity were used (Acrodisc® GHP, Waters). The C-18(1 gm) cartridges 
6cc single use for laboratory use, were purchased form Waters Company (Milford, MA, USA). 
 
Dopamine ProD 1 intraconversion analysisin 0.1N HCl, buffer pH 2.2 and buffer pH 5.5 were done at 
Al-Quds University by using HPLC device with 10 cm column length, while at Jerusalem 
Pharmaceutical company, the column length was 15 cm for dopamine ProD 1 in buffer pH 7.4, and for 
dopamine ProD 2 in 0.1N HCl, buffer pH 2.2, buffer pH 5.5 and buffer pH 7.4. 
3.1.1.3.3 pH meter  
 
pH values were recorded by pH meter model HM-30G: TOA electronics ™ was used to measure  pH 
values for prepared buffers. 
3.1.1.3.4  FT-IR 
All infrared spectra (FTIR) were obtained from KBr (potassium bromide) matrix(4000–400 cm-
1
) using a Perkin Elmer Precisely, Spectrum 100, FT-IR spectrometer. 
3.1.1.3.5 Nuclear magnetic resonance spectroscopy (
1
H -NMR) 
All 
1
H-NMR spectra were conducted using the 400 MHz Varian NMR spectrometer. The 
experimental samples was run in CD3OD. 
1
H-NMR experiments are stated in parts per million 
(ppm) downfield of TMS. 
The following symbols used for 
1
H-NMR peak investigation: chemical shift (δ ppm), multiplicity 
(s =singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration and coupling constant 
(Hz). All 
1
H-NMR data were analyzed by MestReNova Software. 
 
3.1.1.3.6 Liquid Chromatography- Mass Spectroscopy (LC-MS) 
HPLC–MS/MS Shimadzu prominence high performance liquid chromatography system 
(Shimadzu corp. Japan) was employed to record LC/MS measurements, at Jordan Center For 
Pharmaceutical Research (JPRC). 
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3.1.2 Preparation of dopamine prodrugs 
In a 250 ml round-bottom flask, 1.53g of dopamine (10 mmol) was dissolved in THF (100 ml) 
followed by an addition of 1 equivalent of sodium hydride (0.24g) to the reaction and stirred at 
room temperature for 2 hours, then 3.5 equivalent of hexahydro-4-methylphthalic anhydride 
(5.06 ml) or 1,2 cyclohexanedicarboxilic anhydride (5.4g) was added to the reaction. The flask 
was air-tightened and closed with a flexible rubber stopper. The reaction was left over night at 
room temp for 5 days and monitored by TLC to ensure reaction completion using chloroform 
and methanol (1:3) system as an eluent. When the reaction was completed, 10 ml of water was 
added drop wise to destroy the excess of NaH.  
The solvent was evaporated by the rotary evaporator and the resulting precipitate was washed 
three times with diethyl ether then filtered. Evaporation was done to the filtrate to yield a brown 
product. The product was characterized by M.P, H-NMR, FTIR and LC-MS. 
Reaction of dopamine with hexahydro-4-methyl phthalic anhydride or 1,2 cyclohexane 
dicarboxilic anhydride provided dopamine ProD 1 and ProD 2,respectively with yield 90%, 95%, 
respectively (Schemes 2 and 3). M.P. 180oC and178oC, respectively. 
 
Dopamine ProD 1,
1
H-NMR δ (ppm) CD3OD - 0.96 (CH3-CH-CH2, d), 1.43 (CH3-CH-CH2-
CH2, m), 1.76 (CH3-CH-CH2-CH), t), 1.91 (CH3-CH-CH2-CH2-CH, m), 2.25 (NH-CH2-CH2, 
t), 2.46 (HOOC-CH-CH2-CH-CH3, m), 2.98 (NH-C=O-CH, m), 3.32 (NH-CH2-CH2, t), 6.68 
(aromatic, M). IR (KBr/νmax cm
–1
) 1693 (C=O), 3395 (NH), 2800-3000 (OH). LC-MS (positive 
mode) m/z 322.1 (M+1)
+
. 
Dopamine ProD 2,
1
H-NMR δ (ppm) CD3OD-1.4 (q, 2H, HN-C=O-CH-CH2-CH2), 1.74 (m, 2H, 
COOH-CH-CH2-CH2-CH2),  1.81 (m, 2H, HN-C=O-CH-CH2-CH2-CH2), 2.2 (m, 2H, COOH-
CH-CH2-CH2), 2.65 (m, 1H, COOH-CH), 2.85 (t, 2H, HN-CH2-CH2-Ar), 3.2 (m, 1H, COOH-
CH-CH-CH2), 3.6 (t, 2H, HN-CH2-CH2), 6.55 (m, 3H, Aromatic). IR (KBr/νmax cm
–1
) 1692 
(C=O), 3396 (NH), 2800-3000 (OH). LC-MS (positive mode) m/z 308.2 (M+1)
 +
. 
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Scheme 1. Dopamine ProD 1;Synthesis scheme for the formation of dopamine hexahydro-4-methyl phthalate 
reaction 
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Scheme 2. Dopamine ProD 2;Synthesis scheme for the formation of dopamine 1,2 cyclohexane dicarboxilic 
reaction 
 
3.2. Part Two 
3.2.1 Kinetic Methods 
3.2.1.1 Buffer Preparation 
Potassium dihydrogen phosphate (6.8 g) were dissolve in 900 ml water for HPLC, the pH of 
buffer pH 2.2 was adjusted by diluted  o-phosphoric acid and water was added to a final volume 
of 1000 ml. The same procedure was done for the preparation of buffers pH 5.5 and 7.4, 
however, the required pH was adjusted using 1 N NaOH. 0.1N HCl was prepared by diluting 8.5 
ml of hydrochloric acid with water to 1000 ml. 
Intra-conversion of 500 ppm dopamine ProD 1 and dopamineProD2solutions, in 0.1N HCl, 
buffer pH 2, buffer pH 5.5 or buffer pH 7.4, to its parent drug, dopamine, was followed by HPLC 
at a wavelength of 247 nm. Conversion reactions were run mostly at 37 ˚C.  
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3.2.1.2 Calibration curve 
 
A stock solution of dopamine ProD 1or ProD 2 (100 ml) with a final concentration of 500 ppm 
were prepared by dissolving 50 mg from each prodrug in 100 ml methanol. The following 
diluted solutions were prepared from the stock solution: 100, 200, 300 and 400 ppm. To 
construct a calibration curve for dopamine and dopamine ProD1-2, 5 calibrants (100, 200, 300, 
400 and 500 ppm) were prepared. Then, 20 μl of each solution was injected to the HPLC 
apparatus using 250 mm x 4.6 mm, 5 µm C18 XBridge ® column. Methanol and deionized water 
(0.1% v/v acetic acid) with a ratio of 60:40 was used as mobile phase with a flow rate of 1 ml 
min
-1
 and UV detection at a wavelength of 247 nm [167 ].  
Peak area vs. concentration of the pharmaceutical (ppm) was then plotted, and R
2 
of the plot was 
recorded. 
3.2.1.3 Preparation of standard and sample solution 
A 500 ppm of standard dopamine was prepared by dissolving 50 mg of dopamine  in 100 ml of 
0.1N HCl, buffer pH 2.2, buffer pH 5.5 or buffer pH 7.4 and then each sample was injected into 
HPLC to detect the retention time of dopamine. 
A 500 ppm of dopamine  ProD 1 and ProD 2 was prepared by dissolving 50 mg of dopamine  
ProD 1 and ProD 2 in 100 ml of 0.1N HCl, buffer pH 2.2, buffer pH 5.5 or buffer pH 7.4 then 
each sample was injected into HPLC to detect the retention time of dopamine  ProD 1 and ProD 
2. 
The progression of the reaction was followed by monitoring the disappearance of prodrug and 
the appearance of the parent drug (dopamine) with time. 
 
3.3 Part three 
3.3.1 Prediction of drug-likeness and in silico ADMET studies 
In silico prediction methods represent an alternative approach and aim to rationalize the 
preclinical drug development, thus enabling the reduction of the associated time, costs and 
animal experiments [168].  
3.3.1.1  BBB permeability prediction  
Predicting blood-brain barrier (BBB) permeability is essential to drug development, as a 
molecule cannot exhibit pharmacological activity within the brain parenchyma without first 
investigating this barrier. 
In silico BBB permeability were predicted using Online BBB predictor (Prof Xiang-Qun (Sean) 
Xie, Pitt.edu) at http://www.cbligand.org/BBB/ for the synthesized prodrugs. This uses 
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AdaBoost and SVM combining with 4 different fingerprints to predict if a compound can pass 
the BBB(BBB+) or cannot pass the BBB(BBB-). 
3.3.1.2 In silico prediction of physicochemical parameters and ADMET properties 
In silico pharmacokinetics and toxicities were predicted for the two dopamine prodrugs since 
ADMET (absorption, distribution, metabolism and excretion and toxicity) can be a major cause 
of failure of drug candidates during the later phases of drug development. 
Two software were used to calculate the physiochemical properties and to predict ADMET. The 
first one is ACD/Lab software (Advanced Chemistry Development Inc, Ontario, Canada) [169], 
which can predict physicochemical, ADME, and toxicity properties from structure of the 
compound. The second software is an online webserver, admetSAR [170] which provides a 
number of ADMET values for a certain chemical structure to be encoded as SMILES (simplified 
molecular input line entry specification). AdmetSAR is a knowledge based tool comprising of 
ADMET related properties taken from wide range literature which are further used to predict 
properties of unknown compounds. 
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Results and Discussion 
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Chapter Four 
Results and Discussion Part 
 
We have successfully obtained two antiparkinson’s prodrugs of dopamine with two different 
linkers. They were characterized by melting points, FT-IR, 
1
H-NMR and LC-MS analytical 
techniques, to guarantee pure dopamine prodrugs that are expected to give better bioavailability 
than the parent drug owing to improved absorption and are capable of releasing the parent drug 
in a sustained release manner.  
 
4.1Prodrugs characterization using different analytical techniques 
4.1.1Melting point, FT-IR, NMR and LC-MS analysis of dopamine ProD 1 
 
1) Melting point of dopamine ProD 1 was 180 ˚C.  
2) IR (KBr/νmax cm
–1
) 1693 (C=O), 3395 (NH), 2800-3000 (OH). 
3) 
1
H-NMR δ (ppm) CD3OD - 0.96 (CH3-CH-CH2, d), 1.43 (CH3-CH-CH2-CH2, m), 1.76 
(CH3-CH-CH2-CH), t), 1.91 (CH3-CH-CH2-CH2-CH, m), 2.25 (NH-CH2-CH2, t), 2.46 
(HOOC-CH-CH2-CH-CH3, m), 2.98 (NH-C=O-CH, m), 3.32 (NH-CH2-CH2, t), 6.68 (aromatic, 
M).  
4) The product molecular formula is C17H23NO5 (yield 90%). LC-MS (positive mode) m/z 322.1 
(M+1)
+
 (Figure 15d).  
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Figure 15 a: FT-IR spectrum of dopamine ProD 1 (500-4000 cm
-1
). 
 
 
 
Figure 15 b: FT-IR spectrum of dopamine ProD 1 (500-2000 cm
-1
). 
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Figure 15 c: 
1
H-NMR spectrum of dopamine ProD 1. 
 
 
 
Figure 15 d: LC-MS spectrum of dopamine ProD 1. 
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4.1.2 Melting point, FT-IR, NMR and LC-MS analysis of dopamine ProD 2 
 
1) Melting point of dopamine ProD 2 was 178 ˚C.  
2) IR (KBr/νmax cm
–1
)1692 (C=O), 3396 (NH), 2800-3000 (OH).  
3) 
1
H-NMR δ (ppm) CD3OD - 1.4 (q, 2H, HN-C=O-CH-CH2-CH2), 1.74 (m, 2H, COOH-CH-
CH2-CH2-CH2),  1.81 (m, 2H, HN-C=O-CH-CH2-CH2-CH2), 2.2 (m, 2H, COOH-CH-CH2-
CH2), 2.65 (m, 1H, COOH-CH), 2.85 (t, 2H, HN-CH2-CH2-Ar), 3.2 (m, 1H, COOH-CH-CH-
CH2), 3.6 (t, 2H, HN-CH2-CH2), 6.55 (m, 3H, Aromatic). 
4) The product molecular formula is C16H21NO5 (yield 95%). LC-MS (positive mode) m/z 308.2 
(M+1) (Figure 16 d). 
 
 
 
 
 
Figure 16  a: FT-IR spectrum of dopamine ProD 1 (500-4000 cm
-1
) 
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Figure 16 b: FT-IR spectrum of dopamine ProD 1 (500-2000 cm
-1
) 
 
 
 
Figure 16 c: 
1
H-NMR spectrum of dopamine ProD 2 
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Figure 16 d. LC-MS spectrum of dopamine ProD 2. 
 
 
 
4.1.3 Melting point, FT-IR, and NMR analysis of dopamine standard 
1) Melting point of dopamine was 128 ˚C.  
2) IR (KBr/νmax cm
–1
) 1600-1620 (NH bending), 3345 (OH). 
3) 
1
H-NMR δ (ppm) CD3OD: 2.55 (t, 2H, H2N-CH2-CH2), 2.75 (t, 2H, H2N-CH2-CH2), 6.6 
(m, 3H, Aromatic). 
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Figure 17 a:  FT-IR spectrum of dopamine (500-4000 cm
-1
) 
 
 
 
Figure 17 b: FT-IR spectrum of dopamine (500-2000 cm
-1
) 
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Figure 17 c: 
1
H-NMR spectrum of dopamine 
 
 
4.2 calibration curves of dopamine prodrugs 
The calibration curves were obtained by plotting peak area versus concentration. As shown in 
Figure 18excellent linearity with regression (R
2
) of 0.997 and 0.999 for dopamine ProD 1 and 
ProD2 was obtained, respectively. 
 
 
Figure 18: Calibration curves for dopamine ProD 1 and ProD 2 
 
y = 913.1x + 117.6 
R² = 0.997 
0
100000
200000
300000
400000
500000
0 200 400 600
A
re
a 
u
n
d
e
r 
th
e
 p
e
ak
 
Concentration (PPM) 
Dopamine ProD 1 calibration curve 
y = 729.0x - 2623 
R² = 0.999 
0
100000
200000
300000
400000
0 200 400 600
A
re
a 
u
n
d
e
r 
th
e
 p
e
ak
 
Concentration (PPM) 
Dopamine ProD 2 calibration curve 
 39 
4.3 Hydrolysis studies 
The kinetics of the acid-catalyzed hydrolysis studies were carried out in aqueous buffer in the 
same manner as that done by Kirby on Kirby’s enzyme model 1-9 [73]. This is in order to 
explore whether the prodrug hydrolyzes in aqueous medium and to what extent or not, 
suggesting the fate of the prodrug in the system. Acid-catalyzed hydrolysis kinetics of the 
synthesized dopamine ProD 1 and ProD 2 were studied in four different aqueous media, 0.1N 
HCl, buffer pH 2.2, buffer pH 5.5 and buffer pH 7.4 (Table 1 and 2). Under the experimental 
conditions the target compounds hydrolyzed to release the parent drug as evident by HPLC 
analysis, at constant pH and temperature the reaction displayed strict first order kinetics as the 
kobs was fairly constant and a straight plot was obtained on plotting ln concentration of residual 
prodrug vs. time. The rate constant (kobs) and the corresponding half-lives (t1/2) for dopamine 
prodrugs in the different media were calculated from the linear regression equation correlating 
the ln concentration of the residual prodrug vs. time. The 0.1N HCl and pH 2.2 were selected to 
examine the intra-conversion of the dopamine prodrug in pH as of stomach, because the 
meanstomach pH of adult is approximately 1-3. In addition, buffer pH 5.5 mimics the beginning 
of the small intestine pathway. pH 7.4 was selected to examine the intra-conversion of the tested 
prodrugs in the blood circulation system. At pH 5.0-7.4 the carboxylic group in prodrugs ProD 1 
and ProD 2 will equilibrate with the corresponding carboxylate form. Subsequently, the free acid 
form will undergo proton transfer reaction (rate limiting step) after being transferred through the 
membrane to yield dopamine and the inactive linker as a byproduct. The proposed prodrugs 
ProD 1- ProD 2 will be exploited for oral use in the form of enteric coated tablets. It is well 
known, that enteric coated tablets are stable at a high acidic pH found in the stomach, but break 
down rapidly at a less acidic pH. For example, the enteric coated tablets will not dissolve in the 
acidic juices of the stomach (pH ~3), but they will be dissolved in the higher pH (above pH 5.5) 
present in the small intestine. In the intestine, prodrugs ProD 1- ProD 2 will exist in the acidic 
and ionic forms where the equilibrium constant for the exchange between both forms is 
dependent on the pKa of the given prodrug. The experimental determined pKas for ProD-1- 
ProD 2 linkers are in the range of 5.0-6.0. Therefore, it is expected that the pKas of the 
corresponding prodrugs will be in the same range. Since the pH for the small intestine lies in the 
range of 5.0-7.5, the calculated unionized (acidic) /ionized ratio will be 40-50%. Although the 
percentage of the acidic form is not significantly high, we anticipate that prodrugs undergoing an 
efficient proton transfer (rate limiting step) to yield dopamine and Kemp‘s carboxylic acid by-
products and will have the potential to be effective prodrugs. In the blood circulation (pH 7.4), 
the calculated acidic form for those prodrugs is around 10- 30% and it is expected that the rate 
for delivering the parent drug will be reduced. 
Amidase specific activation was done for these two dopamine prodrugs in Finland, the results 
revealed that ProD 1and ProD 2 have found to be non-specific for amidase in the first 24 hours. 
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Table 1: The observed k value and t1/2 for the intraconverion of dopamineProD 1in 0.1N HCl, 
pH 2.2, pH 5.5 and pH 7.4. 
Medium kobs (h
-1
) t½ (h) 
0.1N HCl 0.0115 60.30 
Buffer pH 2.2 0.0126 54.66 
Buffer pH 5.5 0.0069 99.93 
Buffer pH 7.4 0.005 138.13 
 
Table 2: The observed k value and t1/2 for the intraconverion of dopamineProD 2in 0.1N HCl, 
pH 2.2, pH 5.5 and pH 7.4. 
Medium kobs (h
-1
) t½ (h) 
0.1N HCl 0.0143 48.34 
Buffer pH 2.2 0.0128 54.22 
Buffer pH 5.5 0.0052 131.98 
Buffer pH 7.4 0.0036 193.42 
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Figure 19. Chromatograms showing the intra-conversion of dopamine ProD 1 at 0.1N HCl (a) after one hour, 
(b) after 120 hours. 
 
Figure 20. Chromatograms showing the intra-conversion of dopamine ProD 1 at pH 2.2 (a) after one hour 
and (b) after 144 hours. 
 
 
Figure 21. Chromatograms showing the intra-conversion of dopamine ProD 1 at pH 5.5 (a) after 48 
hour, (b) after 144 hours. 
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Figure 22. Chromatograms showing the intra-conversion of dopamine ProD 1 at pH 7.4 (a) after 24 hours, (b) 
after 48 hours and (c) after 216 hours. 
 
 
Figure 23. Chromatograms showing the intra-conversion of dopamine ProD 2 at 0.1N HCl (a) after 4 hours 
and (b) after 72 hours. 
 
 
Figure 24. Chromatograms showing the intra-conversion of dopamine ProD 2 at pH 2.2 (a) after 4 hours and 
(b) after 72 hours. 
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Figure 25. Chromatograms showing the intra-conversion of dopamine ProD 2 at pH 5.5 (a) after 12 hours 
and (b) after 48 hours. 
 
 
Figure 26. Chromatograms showing the intra-conversion of dopamine ProD 2 at pH 7.4 (a) at the start of 
reaction and (b) after 216 hours. 
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Figure 27. First order hydrolysis plot for dopamine ProD 1 in (a) 0.1N HCL, (b) buffer pH 2.2, (c) buffer pH 
5.5 and (d) buffer pH 7.4. 
 
 
 
Figure 28. First order hydrolysis plot for dopamine ProD 2 in (a) 0.1N HCL, (b) buffer pH 2.2, (c) buffer pH 
5.5 and (d) buffer pH 7.4. 
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4.4 Prediction of drug-likeness and in silico ADMET studies 
A.  Matching  with Lipinski’s rule of five: 
The medicinal chemist Christopher Lipinski and his colleagues analyzed the physicochemical 
properties of more than 2,000 drugs and candidate drugs in clinical trials, and concluded that 
90% of orally active drugs that have achieved phase II clinical status were associated with four 
simple physicochemical parameter ranges: molecular weight < 500, log P < 5, H-bond donors < 
5 and H-bond acceptors < 10). Therefore, if a compound matches these physicochemical 
parameters, it is more likely to be membrane permeable and easy to be absorbed through 
membranes and possess the properties of drug like molecules [171]. 
In an attempt to improve the predictions of druglikeness, the rules have been extended to include, 
for example the following criteria: partition coefficient (log P) range −0.4 to +5.6, molar 
refractivity range 40 to 130, molecular weight range 180 to 500, total number of atoms range 20 
to 70 and polar surface area not greater than 140 Ǻ2 [172].  
The results of physicochemical properties revealed that the synthesized dopamine prodrugs were 
within the acceptable limit and comply with Lipinski’s rule of five. 
 
B. Determination of molecular lipophilicity (log P) and aqueous solubility (log S) of dopamine 
prodrugs 
 
The log P and log S coefficients are well-known as the principal parameters for the estimation of 
lipophilicity and solubility of drugs and these two parameters significantly affect the 
pharmacokinetic properties of the drugs [173]. 
 
1. Aqueous Solubility (log S) 
The aqueous solubility of a compound largely affects its absorption and distribution 
characteristics. Typically, a low solubility goes along with a poor absorption and therefore the 
general aim is to avoid poorly soluble compounds. Log S value is a unit stripped logarithm (base 
10) of the solubility measured in mol/liter. Aqueous solubility is an important requirement for a 
CNS drug, as demonstrated by Alelyunas, who determined the solubility of 98 marketed CNS 
drugs in buffer pH 7.4. Over 85% of the drugs tested had high aqueous solubility (>100 uM) 
[174]. Another study showed that more than80% of the drugs on the market have logS values 
greater than -4 and less than 0 [173]. Both dopamine prodrugs were within this limit. 
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2. Molecular lipophilicity (log P) 
Lipophilicity is a main physicochemical determinant influencing the bioavailability, permeability 
and the toxicity of drugs. Thus the 1-octanol/water partition coefficient is the ratio of the 
unionized compound concentration in 1-octanol to its concentration in water. Hence this 
coefficient is a measure of differential solubility of the compound between these two solvents. 
Usually one of the chosen solvents is water, while the second one is hydrophobic, such as 1-
octanol. Both the partition and distribution coefficient are measures of how hydrophilic (“water 
loving”) or hydrophobic (“ water fearing”) a chemical substance is. Moderately lipophilic drugs 
cross the blood brain barrier (BBB) by passive diffusion [173]. For several classes of CNS active 
substances, Hansch and Leo found that BBB penetration is optimal when the Log P values are in 
the range of 1.5-2.7 [175]. Results revealed that log P values for the synthesized dopamine 
prodrugs were found to be within the acceptable limit. 
C. Prediction of oral bioavailability 
Oral bioavailability measurements in rats for over 1100 drug candidates wereconducted at 
SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) to analyze the relative 
importance of molecular properties considered to influence the oral bioavailability of drug 
candidates. Their observations suggest that compounds which meet only the two criteria of (1) 
10 or fewer rotatable bonds and (2) polar surface area  (PSA) equal to or less than 140 Å
2
 (or 12 
or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability 
in the rat [176].  The results of molecular properties found that the two dopamine prodrugs have 
met with these two criteria and the predicted oral bioavailability was approximately 30% for both 
of them which is more than the marketed drugs bioavailability [177]. 
D. Prediction of log D 
In addition, recently van de Waterbeemd et al. have showed that, of a set of 125 drugs, all those 
showing CNS activity could be found within the ranges of -1 ≤ log D (pH 7.5) ≤ 4 [178]. Results 
demonstrated that dopamine ProD 1 was within this range, while dopamine ProD 2 wasn’t.  
E. BBB permeability prediction and in silico log BB studies 
A common measure of the degree of BBB penetration is the ratio of the steady-state 
concentrations of the drug molecule in the brain and in the blood, usually expressed as 
log(Cbrain/Cblood) or, more simply, log BB. Experimental values of log BB published to date 
cover the range about -2.00 to +1.00. Within this range, compounds with log BB > 0.3 cross the 
BBB readily, while compounds with log BB < -1.0 are poorly distributed to the brain [179]. 
BBB permeability software predicts that dopamine ProD 2 has the ability to cross BBB, while 
dopamine ProD 1is not capable to permeate through BBB. 
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Table 3: Molecular properties of dopamine ProD 1 and ProD 2. 
 
 Molecular 
weight 
No. of 
Hydrogen 
Bond 
Donors 
No. of 
Hydrogen 
Bond 
Acceptors 
TPSA No. of 
Rotatable 
Bonds 
Molar 
Refractivity 
log P log S Total 
number of 
atoms 
log D at 
pH 7.4 
Drug-like 
properties 
< 500 
[171] 
< 5 [171] < 10 
[171] 
<140 
Ǻ2[176] 
≤10 
[176] 
40 to 130 
[172] 
1.5-2.7 
[175] 
-4< log 
S < 0 
[173] 
20 to 70 
[172] 
-1 ≤ log 
D (pH 
7.5) ≤ 4 
[177]. 
Dopamine 
ProD 1 
321 4 6 106.86 5 84.16 cm
3
 2.39 -3.94 46 -0.39 
Dopamine 
ProD 2 
307 4 6 106.86 5 97.46 cm
3
 1.59 -3.39 43 -1.19 
 
 
F. In silico ADMET prediction  
In silico pharmacokinetic properties and toxicity were predicted for the two dopamine prodrugs, 
and the results are shown in Table 5. The results of the pharmacokinetic and toxicity predictions 
revealed that no prodrug had a high risk of toxicity, and all the prodrugs showed good 
pharmacokinetic properties. 
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Table 4: ADMET  (absorption, distribution, metabolism, excretion and toxicity) prediction of 
dopamine ProD 1 
Absorption 
Blood-Brain Barrier BBB- 
Human Intestinal Absorption HIA+ 
Caco-2 Permeability Caco2- 
Oral bioavailability Approximately 30 % 
Passive transport  
Good(More than 70%) passive absorption across 
intestinal barrier 
Active transport Not transported 
Plasma protein binding (%PPB) 87.47% 
Log  BB -0.47 
Metabolism 
CYP450 2C9 Substrate Non-substrate 
CYP450 2D6 Substrate Non-substrate 
CYP450 3A4 Substrate Substrate 
CYP450 1A2 Inhibitor Non-inhibitor 
CYP450 2C9 Inhibitor Non-inhibitor 
CYP450 2D6 Inhibitor Non-inhibitor 
CYP450 2C19 Inhibitor Non-inhibitor 
CYP450 3A4 Inhibitor Non-inhibitor 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 
Toxicity 
Human Ether-a-go-go-Related 
Gene Inhibition 
Weak inhibitor 
Non-inhibitor 
AMES Toxicity Non AMES toxic 
Carcinogens Non-carcinogens 
Fish Toxicity High FHMT 
Tetrahymena Pyriformis Toxicity High TPT 
Honey Bee Toxicity Low HBT 
Biodegradation Not ready biodegradable 
Acute Oral Toxicity III 
Carcinogenicity (Three-class) Non-required 
Genotoxicity Hazards No hazards fragment have been found 
Acute toxicity ( LD50, mg/kg ) 
Species/Administration 
route 
LD50 
(mg/kg) 
Mouse/Intraperitoneal 120 
Mouse/Oral 1500 
Mouse/Intravenous 490 
Mouse/Subcutaneous 1000 
Rat/Intraperitoneal 280 
Rat/Oral 3800 
 
Endocrine disruption  No binding to estrogen receptor alpha 
MRDD (Max. recommended daily 
dose) 
1.15 mg/kg/day 
Toxicity effect  
(Information on whether 
predicted  rodent acute toxicity 
values provide any indication that 
the compound can be unsafe at 
higher dosage) 
 
 
Gastrointestinal  Safe 
Lungs Safe 
Cardiovascular Safe 
Liver Could be 
unsafe  
Blood Safe 
Kidny Safe 
Predicted oral LD50 >1000 mg/kg 
Predicted intravenous LD50 >200 mg/kg 
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Table 5:ADMET  (absorption, distribution, metabolism, excretion and toxicity) prediction of 
dopamine ProD 2 
Absorption 
 
Blood-Brain Barrier BBB+ 
Human Intestinal Absorption HIA+ 
Caco-2 Permeability Caco2- 
Oral bioavailability Approximately 30 % 
Passive transport  
Moderate (between 40% and 70%) passive 
absorption across intestinal barrier 
Active transport Not transported 
Plasma protein binding (%PPB) 76.22% 
Log BB -0.43 
Metabolism 
CYP450 2C9 Substrate Non-substrate 
CYP450 2D6 Substrate Non-substrate 
CYP450 3A4 Substrate Non-substrate 
CYP450 1A2 Inhibitor Non-inhibitor 
CYP450 2C9 Inhibitor Non-inhibitor 
CYP450 2D6 Inhibitor Non-inhibitor 
CYP450 2C19 Inhibitor Non-inhibitor 
CYP450 3A4 Inhibitor Non-inhibitor 
CYP Inhibitory Promiscuity Low CYP Inhibitory Promiscuity 
Toxicity 
Human Ether-a-go-go-Related 
Gene Inhibition 
Weak inhibitor 
 Inhibitor 
AMES Toxicity Non AMES toxic 
Carcinogens Non-carcinogens 
Fish Toxicity High FHMT 
Tetrahymena Pyriformis Toxicity High TPT 
Honey Bee Toxicity Low HBT 
Biodegradation Ready biodegradable 
Acute Oral Toxicity III 
Carcinogenicity (Three-class) Non-required 
Genotoxicity Hazards No hazards fragment have been found 
Acute toxicity ( LD50, mg/kg ) 
Species/Administration 
route 
LD50 
(mg/kg) 
Mouse/Intraperitoneal 110 
Mouse/Oral 1600 
Mouse/Intravenous 590 
Mouse/Subcutaneous 1100 
Rat/Intraperitoneal 290 
Rat/Oral 3000 
 
Endocrine disruption  No binding to estrogen receptor alpha 
MRDD (Max. recommended daily 
dose) 
1.13 mg/kg/day 
Toxicity effect  
(Information on whether 
predicted  rodent acute toxicity 
values provide any indication that 
the compound can be unsafe at 
higher dosage) 
 
 
Gastrointestinal  Safe 
Lungs Safe 
Cardiovascular Safe 
Liver Could be unsafe  
Blood Safe 
Kidny Safe 
Predicted oral LD50 >1000 mg/kg 
Predicted intravenous LD50 >200 mg/kg 
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Chapter Five 
 
Conclusions and Future directions 
5.1. Conclusions 
 
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the loss of 
dopaminergic neurons of the substantia nigra pars compacta. Current therapy is essentially 
symptomatic, and L-Dopa (LD), the direct precursor of dopamine(DA), is the treatment of choice 
in more advanced stages of the disease. Substitution therapy with LD is, however, associated 
with a number of acute problems. The peripheral conversion of LD by amino acid decarboxylase 
(AADC) to DA is responsible for the typical gastrointestinal (nausea, emesis) and cardiovascular 
(arrhythmia, hypotension) side effects. To minimize the conversion to DA outside the central 
nervous system (CNS), LD is usually given in combination with peripheral inhibitors of AADC 
(carbidopa or benserazide). In spite of that, other central nervous side effects such as dyskinesia, 
on-off phenomenon and end-of-dose deterioration still remain.  
 
In order to improve the bioavailability, the prodrug approach appeared to be the most promising 
approach.  Therefore, there was a need to synthesize new prodrugs for the treatment of 
Parkinson's disease having higher bioavailability than the current medications and have the 
potential to release DA in a sustained manner. 
 
Based on the DFT calculations on proton transfer mechanism of Kemp‘s acid amides, two 
dopamine derivatives were designed, synthesized and characterized. These prodrugs have a 
carboxylic group as a hydrophilic moiety and the rest of the prodrug as a lipophilic moiety, 
where the combination of both moieties secures a moderate HLB. Furthermore, at physiological 
pH in the blood circulation the expected predominant form of dopamine is the ionized form 
while its prodrugs will exist in the ionic and free acid forms. Therefore, dopamine ProD 1 and 
dopamine ProD 2 may have a higher bioavailability than dopamine due to improved absorption. 
Also, the synthesized prodrugs can be used in many dosage forms (e.g. enteric coated tablets) 
because they are soluble in organic and aqueous media due to the ability of the carboxylic group 
to be converted to the corresponding carboxylate anion in physiological environments of pH 5.0-
7.4 (intestine and blood circulation). The in vitro intra-conversion of these prodrugs to their 
parent drug, dopamine, revealed that the t1/2 was largely affected by the pH of the medium. For 
dopamine ProD 1 the experimental t1/2 values in 0.1N HCl, buffer pH 2, buffer pH 5.5 and buffer 
pH 7.4 were 60.3hours, 54.66 hours, 99.93 hours and 138.13 hours, respectively. Dopamine 
ProD 2 was readily converted in 0.1N HCl and pH 2, pH 5.5 and pH 7.4 with half -life time (t½) 
of 48 hours, 54.22 hours, 131.98 hours and 193.42 hours, respectively. In silico prediction of the 
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pharmacokinetic and toxicity revealed that no prodrug has a high risk of toxicity, and all the 
prodrugs showed good pharmacokinetic properties. Moreover, all prodrugs complied with 
Lipinski’s rule of five. 
5.2. Future directions 
Our future directions are to evaluate if our newly synthesized prodrugs haveanti-Parkinson 
activity. In addition, in vivo pharmacokinetic studies will be launched in order to determine the 
bioavailability and the duration of action of the tested prodrugs.  
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 تصنيع ودراسة المواصفات والقوى المحركة المخبرية للأدوية المساعدة للدوبامين
 
  يحيى فؤاد رشيد خواجا إعداد: 
 
 بروفيسور رفيق قرمانإشراف: 
 
 : ملخص
في   )enimapod() يعانون من نقص في مادة الدوبامينnosnikraPمن المعروف أن مرضى الباركنسون (
الدوبامين. الدوبامين وحده لا يمر من  لذلك كانت المحاولات لتعويض هذا النقص من ،مناطق معينه في الدماغ
از العصبي المركزي هاستطاع العبور إلى الج )apodoveLالليفودوبا (الحاجز الدموي الدماغي لكن طليعه 
) عن طريق الفم  كان التوافر الحيوي DL) ليتم تحويله الى الدوبامين في الدماغ. عند اعطاء الليفودوبا (SNC(
الكثير % من الجرعة تخترق الدماغ. جرعات كبيرة من الليفودوبا مطلوبة، لأن  1% مع أقل من 11له أقل من 
الآثار الجانبية التي تشمل الغثيان، التقيؤ، عدم انتظام  منه يتم تحويله إلى الدوبامين خارج الدماغ مما يؤدي إلى
) SNCضربات القلب وانخفاض ضغط الدم. للحد من التحويل إلى الدوبامين خارج الجهاز العصبي المركزي(
من  )puorg lyxobrac( مجموعة الكربوكسيل ن نزعالمسئول ع عادة ما يعطى الليفودوبا مع مثبط الإنزيم
 عصبية آثار ذلك، من الرغم على). يدابنسيراز و كاربيدوبا( )edizaresneb ,apodibraC(الدوبامين مثل 
 .قائمة تزال لا الجرعة الحالة عند نهاية وتدهور الحركة، كخلل في جانبية أخرى مركزية
جديدة للدوبامين لعلاج مرضى الباركنسون حيث كانت  )sgurdorPتم تصنيع طلائع ( TFDبناء على حسابات 
هذه الطلائع لديها مجموعة الكربوكسيل المحبة للماء ومجموعة الهيدروكربون المحبة للدهون حيث أن الجمع بين 
توافر حيوي  )sgurdorP( . من المتوقع أن يكون لهذه الطلائعBLHكلتا المجموعتين يضمن توازن في قيمة 
من الدواء الأم بسبب تحسن امتصاص طلائع الدوبامين المحتمل. علاوة على ذلك، يعتقد بان هذه الطلائع  أعلى
 إلى الوصول الخارجي قبل المحيط في الكربوكسيل لنزع يخضع الأخير هذا لها فعالية أكثر من الليفودوبا، لأن
 مختلفة أشكال صيدلانية في استخدامها يمكن المصنعة الدوبامين طلائع ذلك، إلى بالإضافة. الدموي الدماغ حاجز
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ة دراس بعد .والمائي العضوي الوسطين في المحتمل الذوبان بسبب) بالوريد، تحت الجلد، أقراص،وغيرها(
 enimapoDتتأثر إلى حد كبير بدرجة حموضة الوسط.  ل  2/1t أنإلى الدواء الأصلي وجد  حويل هذه الأدويةت
و درجة  2.2، درجة حموضة  lCH N1.0 حمض الهيدروكلوريدفي  2/1tكانت النتائج التجريبية لل  1 DorP
في  .ساعات 61..61و ساعة 69.99 ساعة، 33.45 ساعة، 6.13 كالتالي 4.7ودرجة حموضه  5.5حموضة 
، درجة )lCH N1.0( حمض الهيدروكلوريدفي  2 DorP enimapoD ل  التجريبية 2/1t المقابل، كانت قيم
 ساعة .9.161 ساعة، 22.45 ساعة، 46..4كالتالي  4.7ودرجة حموضة  5.5و درجة حموضة  2.2حموضة 
لهذه الطلائع بالإضافة  وأخيرا تم التنبؤ بالخصائص الفيزيوكيميائية ودرجة السمية .التوالي ساعة على 24.691و
 على المرور من الحاجز الدموي الدماغي.إلى التوافر الحيوي ومعرفة إذا كانت هذه الطلائع لها القدرة 
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